Fortitude Family Office’s HCW Biologics HCWB Stock Holding History

Fortitude Family Office’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10	Closed	-$230	–	2050
2025 Q2	$230	Buy	+10	New	+$436	﹤0.01%	1949

Other funds holding HCWB

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Fortitude Family Office's HCWB Position: Q3 2025 in Review

Fortitude Family Office sold out of HCW Biologics (HCWB) in Q3 2025, closing a stake of 10 shares — an estimated $230 sold.

Fortitude Family Office first reported a position in HCWB in Q2 2025 and held it in 1 quarter. The position peaked at $230 in Q2 2025. 9 funds tracked by Wall St. Rank hold HCWB as of Q3 2025.

Fortitude Family Office reported no remaining HCW Biologics position as of Q3 2025 after selling out during the quarter.
Fortitude Family Office sold 10 HCW Biologics shares in Q3 2025, an estimated $230.
Fortitude Family Office first reported a position in HCW Biologics in Q2 2025 and held it in 1 quarter.
Fortitude Family Office's HCW Biologics position peaked at $230 in Q2 2025.
9 funds tracked by Wall St. Rank held HCW Biologics as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.